2m 2m 2m 2m 2m 2m 2m
AYTU BIOPHARMA (AYTU)
NASDAQ
$2.08-$0.010 (-0.48%)
Price as of Oct 02, 2026 4:10 PM EDT- $22.7MMarket Cap
- 6.09%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
AYTU BIOPHARMA (AYTU)
$2.08-$0.010 (-0.48%)
Annual
Quarterly
06/30/2026 | 06/30/2025 | 06/30/2024 | 06/30/2023 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 57.6M -13.27% | 66.4M -18.05% | 81.0M -24.58% | 107.4M +11.10% | |
Cost of Revenue | 20.8M +0.98% | 20.6M -22.20% | 26.4M -35.20% | 40.8M -8.15% | |
Gross Profit | 36.8M -19.67% | 45.8M -16.04% | 54.6M -18.08% | 66.6M +27.44% | |
Sales and Marketing Expense | 23.4M +11.78% | 20.9M -22.45% | 27.0M -34.96% | 41.4M +7.06% | |
Research and Development Expense | 0 +100.00% | -1.3M -52.49% | -2.8M -31.84% | -4.1M -71.64% | |
Depreciation and Amortization Expense | 3.9M -26.91% | 5.4M -35.00% | 8.3M -6.16% | 8.8M -14.01% | |
Total Operating Expenses | 45.1M -15.89% | 53.7M -10.33% | 59.8M -28.50% | 83.7M -48.92% | |
Operating Profit | -8.3M +6.23% | -7.8M +48.97% | -5.3M -69.21% | -17.1M -84.70% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -400,000 +100.00% | -200,000 +100.00% | -100,000 -85.71% | -700,000 -22.22% | |
Interest Income and Expense and Net | -400,000 +100.00% | -200,000 +100.00% | -100,000 -85.71% | -700,000 -22.22% | |
Total Nonoperating Income and Expense | 713,000 +239.26% | -512,000 -190.14% | 568,000 +3,957.14% | 14,000 -98.90% | |
Income before Taxes | -14.2M +3.54% | -13.7M -2.35% | -14.1M -17.45% | -17.1M -84.54% | |
Income Taxes | 21,000 -95.19% | 437,000 -75.28% | 1.8M N/A | 0 +100.00% | |
Extraordinary Items | 0 -100.00% | 8.3M N/A | 0 -100.00% | 5.7M -92.44% | |
Net Income | -14.3M +5.09% | -13.6M -14.40% | -15.8M -7.08% | -17.1M -84.52% | |
Net Income from Continuing Operations Applicable to Common | -14.3M +0.49% | -14.2M +0.75% | -14.1M -17.45% | -17.1M -84.54% | |
Basic EPS and Net Income | -1.16 -46.30% | -2.16 -24.48% | -2.86 -44.03% | -5.11 +50.74% | |
Diluted EPS and Net Income | -1.16 -46.30% | -2.16 -24.48% | -2.86 -44.03% | -5.11 +36.27% | |
Basic Weighted Average Shares | 12.3M +96.17% | 6.3M +13.39% | 5.5M +65.81% | 3.3M -88.64% | |
Diluted Weighted Average Shares | 12.3M +96.17% | 6.3M +13.39% | 5.5M +65.81% | 3.3M -88.64% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 26.3M -15.00% | 31.0M +54.71% | 20.0M -12.96% | 23.0M +18.72% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 26.3M -15.00% | 31.0M +54.71% | 20.0M -12.96% | 23.0M +18.72% | |
Total Current Assets | 61.8M -22.00% | 79.2M +27.93% | 61.9M -15.02% | 72.8M +21.53% | |
Accumulated Depreciation | 809,000 +13.31% | 714,000 -66.40% | 2.1M -42.27% | 3.7M +52.04% | |
Property and Plant and Equipment and Net | 385,000 -27.63% | 532,000 -23.23% | 693,000 -61.82% | 1.8M -40.00% | |
Total Long-Term Assets | 43.2M -3.89% | 45.0M -19.94% | 56.2M -11.67% | 63.6M -18.10% | |
Total Assets | 105.0M -15.44% | 124.2M +5.15% | 118.1M -13.46% | 136.5M -0.84% | |
Income Taxes Payable | 1.3M +18.18% | 1.1M +266.67% | 300,000 +50.00% | 200,000 +100.00% | |
Total Short-Term Debt | 7.9M -27.37% | 10.9M +156.82% | 4.3M +158.01% | 1.6M -57.84% | |
Total Current Liabilities | 54.7M -13.33% | 63.1M +1.34% | 62.2M -9.83% | 69.0M +7.10% | |
Total Long-Term Debt | 9.1M -16.47% | 10.9M +0.17% | 10.9M -26.07% | 14.7M +3.04% | |
Total Long-Term Liabilities | 15.1M -64.23% | 42.1M +49.72% | 28.2M +303.60% | 7.0M -45.55% | |
Total Liabilities | 54.7M -13.33% | 63.1M +1.34% | 62.2M -35.92% | 97.1M +6.09% | |
Retained Earnings | -347.8M +4.27% | -333.5M +4.24% | -320.0M +5.21% | -304.1M +5.43% | |
Total Stockholders Equity | 35.3M +85.99% | 19.0M -31.57% | 27.7M -29.58% | 39.4M -14.61% | |
Total Shares Outstanding | 10.9M +9.63% | 9.9M +65.96% | 6.0M +8.26% | 5.5M -85.70% | |
Cash Flow | |||||
Cash from Operating Activities | 3.3M +269.39% | -1.9M +39.55% | -1.4M -72.94% | -5.1M -82.21% | |
Capital Expenditures | 29,000 -87.28% | 228,000 N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -29,000 -98.87% | -2.6M +678.12% | -329,000 +181.20% | -117,000 -96.40% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -7.9M -151.13% | 15.4M +1,323.69% | -1.3M -114.23% | 8.9M +479.80% | |
Financials Ratio | |||||
Gross Margin | 63.95% -7.37% | 69.04% +2.45% | 67.39% +8.62% | 62.04% +14.71% | |
Operating Margin | -14.44% +22.50% | -11.79% +81.78% | -6.49% -59.18% | -15.89% -86.23% | |
Return on Assets | -12.44% +11.09% | -11.20% -10.06% | -12.45% +0.05% | -12.44% -77.23% | |
Return on Equity | -52.55% -9.56% | -58.10% +22.99% | -47.24% +18.38% | -39.91% -66.74% | |
Revenue Growth | -13.27% -26.45% | -18.05% -26.57% | -24.58% -321.43% | 11.10% -76.53% | |
Current Ratio | 1.13 -10.00% | 1.26 +26.23% | 0.99 -5.75% | 1.06 +13.47% | |
Cash Ratio | 0.48 -1.94% | 0.49 +52.66% | 0.32 -3.45% | 0.33 +10.85% | |
Debt-to-Equity Ratio | 0.48 -58.02% | 1.15 +110.70% | 0.55 +31.32% | 0.42 +5.35% | |
Debt-to-Assets Ratio | 0.16 -7.68% | 0.18 +37.16% | 0.13 +6.84% | 0.12 -9.30% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow